
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA ...
First-in-human Phase 1/2 study initiated for ATX-295, a potential best-in-class oral inhibitor of KIF18A, focused on patients with advanced solid tumors including ovarian cancer FDA grants Fast Track designation to Accent's two lead clinical-stage …